H2020

A revolution in mass electricity storage : ENOGIA will design and deliver the supercritical CO2 turbomachinery of the SCO2OP-TES project

Retrieved on: 
Wednesday, December 20, 2023
SCO2, Carnot battery, Research, Regulatory News Service, RES, Architecture, Turbomachinery, University, H2020, Environment, European, Climate, CO2, Valorisation, Electricity, Renewable energy, Horizon Europe

Capitalizing on more than a decade of high technology turbomachinery research and development, ENOGIA was selected as the main turbomachinery manufacturing partner of the SCO2OP-TES project.

Key Points: 
  • Capitalizing on more than a decade of high technology turbomachinery research and development, ENOGIA was selected as the main turbomachinery manufacturing partner of the SCO2OP-TES project.
  • ENOGIA will design, engineer, manufacture and test the main supercritical CO2 turbomachines used in this project where a groundbreaking Carnot battery architecture will be developed and tested by the partners of the project.
  • This project emphasizes ENOGIA's recognized ability to develop cutting-edge supercritical CO2 turbomachinery, acquired through years of research and several development projects (including the H2020 I-Therm project).
  • Total funding of the project is 4,7M€, including a grant of 875,5 k€ for ENOGIA to support its activities in the project critical hot sCO2 turbomachinery design, manufacturing and testing.

Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection

Retrieved on: 
Thursday, January 19, 2023
Infection, NSCLC, Large-cell lung carcinoma, Secondary research, Pneumonia, Survival rate, Centre for Genomic Regulation, Union, Toxicity, Respiratory tract, Nature Biotechnology, Lluch, H2020, IRB, European Research Council, Lung cancer, Public health, Microbiology, Biotechnology, Biofilm, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, VAP, CRG, Research, Pseudomonas aeruginosa, Lung, Bacteria, Degenerative disease, Immune system, Survival, Patient, Engineering, Mouse, Mortality, European Innovation Council, Synthetic biology, Catalonia, Ventilator-associated pneumonia, Asthma, Enzyme, Inflammation, Doctor of Philosophy, Institute for Research in Biomedicine, Pharmaceutical industry, Vaccine, Science

BARCELONA, Spain, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Pulmobiotics SL, a biotechnology company pioneering novel live biotherapeutics for the treatment of lung diseases, and the Centre for Genomic Regulation (CRG), an international biomedical research institute of excellence whose mission is to discover and advance knowledge for the benefit of society, public health and economic prosperity, today announced the publication of preclinical results demonstrating that treatment using Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant Pseudomonas aeruginosa infections in the lungs of mice, thereby improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with ventilator-associated pneumonia (VAP). These data highlight a promising new approach to treat antibiotic-resistant Pseudomonas aeruginosa lung infections, a leading cause of mortality in hospital settings, and could offer a potential alternative to the use of antibiotics that enable antibiotic resistance, a global public health crisis. Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.

Key Points: 
  • Importantly, these data also support the application of Pulmobiotics’ synthetic biology research platform to discover and develop novel live biotherapeutics for the treatment of other serious lung diseases.
  • This publication is the first time data has been described for a live biotherapeutic for the treatment of lung infection caused by Pseudomonas aeruginosa.
  • The results are published in Nature Biotechnology and this research is supported by the European Research Council through an H2020 project and “la Caixa” Foundation through the CaixaResearch Health Call.
  • Treatment led to a significant reduction in Pseudomonas aeruginosa bacterial load with the Pulmobiotics treatment alone or in combination with ceftolozane/taxobactam antibiotics.

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Retrieved on: 
Wednesday, May 18, 2022
PCP, Software, NGS, SME, Medicine, Medical University of Graz, University of Florence, Pathology, Patient, Erasmus MC, Contract, Workflow, Association, H2020, EQA, Medical school, BC, Research, ELIXIR, DIGITALEUROPE, Partnership, Cancer Research Institute, Program, University, Hospital, Neoplasm, Union, BCP, Technology, Drug development, Precision medicine, Quality control, Intelligence, Ng Hui Ern, DNA sequencing, Cancer, University of Milano-Bicocca, Classification, IP, CEO, Pharmaceutical industry, Medical device, Medical imaging, EU, European, Central Europe

The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.

Key Points: 
  • The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.
  • The joint proposal by BC Platforms, Euformatics and Oncompass Medicine was evaluated by leading experts and selected for funding.
  • Oncompass was the first to develop a software as a medical device based on artificial intelligence that proved to improve therapeutic decisions in precision oncology.
  • Oncompass also provides end-to-end services for oncology centers that wish to provide precision oncology to their patients.

BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals

Retrieved on: 
Wednesday, May 18, 2022
PCP, Software, NGS, SME, Medicine, Medical University of Graz, University of Florence, Pathology, Patient, Erasmus MC, Contract, Workflow, Association, H2020, EQA, Medical school, BC, Research, ELIXIR, DIGITALEUROPE, Partnership, Cancer Research Institute, Program, University, Hospital, Neoplasm, Union, BCP, Technology, Drug development, Precision medicine, Quality control, Intelligence, Ng Hui Ern, DNA sequencing, Cancer, University of Milano-Bicocca, Classification, IP, CEO, Pharmaceutical industry, Medical device, Medical imaging, EU, European, Central Europe

The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.

Key Points: 
  • The buyer consortium, represented by the Medical University Graz, evaluated all proposals, and awarded a contract to the consortium of BC Platforms, Euformatics and Oncompass Medicine.
  • The joint proposal by BC Platforms, Euformatics and Oncompass Medicine was evaluated by leading experts and selected for funding.
  • Oncompass was the first to develop a software as a medical device based on artificial intelligence that proved to improve therapeutic decisions in precision oncology.
  • Oncompass also provides end-to-end services for oncology centers that wish to provide precision oncology to their patients.

Omnix Medical Starts Phase I Clinical Trial of Novel Anti-Infective; First Healthy Volunteers Dosed

Retrieved on: 
Tuesday, April 12, 2022
AMR, Pharmacokinetics, Clinical trial, Mortality, Acinetobacter baumannii, Bacteria, Research, Publication, CSO, QIDP, EIC, IIA, CEO, Prevalence, HIA, Technology, NIH, Gram-negative bacteria, Cell membrane, Infection, H2020, Mall of America, Patient, Brilacidin, Pharmaceutical industry, Vaccine

JERUSALEM, Israel, April 12, 2022 -- Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since March 28, 2022, six healthy volunteers have been administered the novel antimicrobial, which is based on a naturally occuring mechanism of action (MoA) leading to a targeted, effective destruction of the cell membrane of pathogens. The trial is being conducted in Groningen, The Netherlands. OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects. Results are expected by Q4, 2022.

Key Points: 
  • JERUSALEM, Israel, April 12, 2022 -- Omnix Medical , a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6.
  • OMN6 is being evaluated in a randomized, double-blind, placebo-controlled, single ascending dose trial assessing safety, tolerability, and pharmacokinetics of single and repeat IV infusion of the compound in healthy subjects.
  • Dr. Niv Bachnoff, CSO of Omnix Medical, added We are thrilled about the progress of our first clinical trial.
  • Omnix Medical was founded on 2015 to address the urgent unmet need for new life-saving anti-infective drugs.

Dyne.org, RIDDLE&CODE and InfoCert's Consortium Appointed to Take EBSI to the Next Level

Retrieved on: 
Tuesday, September 21, 2021
Professional Services, Data Management, Security, Technology, Software, Finance, Internet, Ethereum, Bitcoin, Crypto, Adoption, Smart city, Hyperledger, ISO, Language, Policy, CTO, Digital Trust Center, SPID, BMW, Solution, Daimler Mobility, Chief innovation officer, Privacy, Executive Vice President of the European Commission for A Europe Fit for the Digital Age, Multimedia, CODE, Service provider, Trust, Freedom, Energy policy of the European Union, Internet of things, European Union, IOT, Digital identity, Founder, Certificate authority, Blockchain, Digital, Agid, European Commission, Digital signature, 2004 Wien Energie Grand Prix, H2020, EIDAS, Citizenship, Web browser, Science and technology in Asia, Certification, Produce traceability, Cryptocurrency, RIDDLE&CODE, Dyne.org, InfoCert, RIDDLE&CODE, DYNE.ORG, INFOCERT

The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations.

Key Points: 
  • The European Commission's vision for EBSI is to leverage distributed ledger technologies to create international and intra-communautaire services for public administrations.
  • The blockchain-agnostic solution offers compatibility with a wide range of products to grant freedom of choice to participating member states and solution developers.
  • Dr. Francesca Bria , president of the Italian National Innovation Fund Cassa Depositi e Prestiti comments: "Zenroom stands for Citizen Crypto.
  • For the initial phase of EBSI's procurement, the consortium proposes a revolutionary solution for a European Digital Product Passport .